CLS and ClearPoint Neuro partner with Dartmouth Health on a $2.98 million NIH-backed study to develop minimally invasive laser therapy for spinal tumors, expanding their neurosurgical technology footprint.
CLS has been selected as an industrial partner in a five-year NIH-funded research program to develop MR-guided laser therapy for spinal metastases, which could expand its technology into a new application.
ClearPoint Neuro is participating as an industrial partner in the same NIH-funded research program, providing its ClearPoint Prism Neuro Laser Therapy System for the spinal metastases study.
Clinical Laserthermia Systems (CLS) and ClearPoint Neuro have been selected as industrial partners for a five-year, $2.98 million research program funded by the U.S. National Cancer Institute. The project aims to advance MR-guided laser therapy for spinal metastases, leveraging the companies' combined expertise in neurosurgical laser technology to improve patient outcomes compared to traditional surgery.
The partnership aims to develop and validate MR-guided laser interstitial thermal therapy (LITT) as a minimally invasive alternative to traditional surgery for treating spinal metastases.
The project is funded by a $2.98 million grant from the U.S. National Cancer Institute (NCI), with the first year fully covered by federal funds.